Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's Oncology Group
C17 Council
Children's Oncology Group
Children's Oncology Group
Nationwide Children's Hospital
St. Jude Children's Research Hospital
Children's Oncology Group
Children's Oncology Group
St. Jude Children's Research Hospital
Hoosier Cancer Research Network
Universitätsklinikum Hamburg-Eppendorf
St. Jude Children's Research Hospital
European Organisation for Research and Treatment of Cancer - EORTC
AbbVie
Chengdu Kanghong Pharmaceutical Group Co., Ltd.
Children's Oncology Group
Memorial Sloan Kettering Cancer Center
Fundación GECP
Children's Oncology Group
Children's Oncology Group
St. Jude Children's Research Hospital
Novo Nordisk A/S
Eastern Cooperative Oncology Group
Xennials Therapeutics Australia Pty Ltd
Children's Oncology Group
National Cancer Institute (NCI)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Taiwan University Hospital
St. Anna Kinderkrebsforschung
Case Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
Canadian Cancer Trials Group
University of Regensburg
Baylor College of Medicine
Baylor College of Medicine
Tufts Medical Center
Children's Hospital of Philadelphia
Children's Oncology Group
Memorial Sloan Kettering Cancer Center
St. Jude Children's Research Hospital
University of Cologne
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
Samsung Medical Center
Dana-Farber Cancer Institute